Science & Medical |
Cube Public Relations

A new first-of-its-kind injectable treatment for the prevention of migraine in adults - Aimovig® - approved in Australia

 A new first-of-its-kind injectable treatment for the prevention of migraine in adults - Aimovig® - approved in Australia

·        Aimovig® (erenumab) has been registered on the Australian Register of Therapeutic Goods (ARTG) for the prevention (prophylaxis) of migraine in adults1

·        It is a 100% human monoclonal antibody and the first in a new class of injectable migraine treatments1

·        Migraine is a complex neurological disease that affects approximately 3.5 million Australians2,3, particularly those of working age3

Sydney, Australia, 22 August 2018 – Aimovig, the first in a new class of long-acting, injectable medications for the prevention of migraine in adults1 has been approved for use in Australia. Aimovig is a calcitonin gene-related peptide (CGRP) receptor blocker1.

CGRP is a neurotransmitter associated with the development of migraine. CGRP levels have been shown to increase significantly during a migraine and return to normal with migraine relief1. Aimovig works by specifically blocking the activity of CGRP molecule1.

Migraine is estimated to affect up to 15% of the population3 making it more common than diabetes, asthma or coronary heart disease3.  Migraine features debilitating headache which can be moderately to severely painful, often pulsating and on one side of the head and is often accompanied by other symptoms such as nausea, vomiting and light or sound sensitivity4.

A recent global study by Novartis and European Migraine and Headache Alliance revealed 60% of employed people with severe migraine miss, on average, a week of work per month5.

Gerald Edmunds, Chief Executive Officer, Headache Australia explains how migraine has a huge impact on quality of life and ability to function for millions of Australians, particularly those of working age3.

“Migraine does not just affect an individual. The impact of a person’s absence or inability to perform daily activities due to migraine extends to their colleagues, family members and social relationships6. We want to help eliminate the intermittent suffering of people with migraine so they can have a normal life.”

Aimovig is self-administered as a subcutaneous (under the skin) injection of 70 mg once every four weeks via a pre-filled pen1. A 140 mg dose every four weeks may also be prescribed.

Professor Tissa Wijeratne Senior Neurologist, Chair, Neurology Western Health; Chair, SIG for Migraine, World Federation of Neuro-Rehabilitation; Chair, Public Awareness and Advocacy, World Federation of Neurology said “Treatments that offer a new approach to managing and preventing migraine are important”.

“The potential to prevent a migraine through this approach is a welcome addition to the treatment options we have available,” he said.

Common adverse events (≥1% and <10%) for Aimovig include injection site reactions, constipation, muscle spasms and pruritus (itchy skin)1. Contraindications are hypersensitivity to erenumab (the active ingredient in this medicine) or to any of the inactive ingredients in this medicine1.

Before taking Aimovig, patients should inform their doctor of any problems with their kidneys or liver, as well as allergies to latex which is contained within the cap of the pen7.

Novartis Pharmaceuticals Australia recognises the need to provide new medicines for people with migraine and welcome Aimovig’s ARTG registration. Novartis looks forward to working with Government to support appropriate patient access via the Pharmaceutical Benefits Scheme (PBS).

The Aimovig Consumer Medicine Information should be referred to for more information. It is available by calling Novartis Medical Information on 1800 671 203 or at


Issued on behalf of Novartis Pharmaceuticals Australia by Cube


PBS Information

This product is not listed on the PBS



About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20m annually in local clinical trials.

Our mission is to discover new ways to improve and extend people’s lives. We are committed to patients, associates, healthcare partners and society at large to improve access to healthcare and essential medicines as we aspire to become a trusted leader in changing the practice of medicine.

For more information, please visit    

Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park, NSW 2113. Telephone 1 800 671 203. Date of preparation: August 2018. AU-7033



1.      Aimovig Approved Product Information

2.      Australian Bureau of Statistics. Australian Demographic Statistics, Dec 2017. Available online at: Accessed August 2018 

3.      Headache Australia. What is Migraine? Available online at: Accessed August 2018

4.      Russo, A.F. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. Annu. Rev. Pharmacy. Toxicol, 2015. 55:533-52.

5.      Novartis Global Press Release. Available online at: Accessed August 2018

6.      World Health Organisation. Headache disorders. Available online at: Accessed August 2018

7.      Aimovig Consumer Medicine Information